Asset Details
Do you wish to reserve the book?
HER2 and Response to Paclitaxel in Node-Positive Breast Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
HER2 and Response to Paclitaxel in Node-Positive Breast Cancer
Do you wish to request the book?
HER2 and Response to Paclitaxel in Node-Positive Breast Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
HER2 and Response to Paclitaxel in Node-Positive Breast Cancer
2007
Overview
The tissue blocks from a large group of women who had participated in a randomized trial of the treatment of node-positive breast cancer were analyzed for the expression of HER2 and the estrogen receptor. A significant interaction was found between HER2 positivity and a benefit from the addition of paclitaxel after adjuvant treatment with doxorubicin plus cyclophosphamide.
A significant interaction was found between HER2 positivity and a benefit from the addition of paclitaxel after adjuvant treatment with doxorubicin plus cyclophosphamide.
Adjuvant chemotherapy improves disease-free and overall survival in early-stage breast cancer,
1
and anthracyclines and taxanes are two of the most active agents in such treatment.
2
The Cancer and Leukemia Group B (CALGB) 8541 trial showed that increasing the dose of a doxorubicin (Adriamycin)–based regimen from a relatively low dose (30 mg per square meter of body-surface area) to what is now considered to be a standard dose (60 mg per square meter) is highly beneficial.
3
,
4
Subsequently, a randomized trial (CALGB 9344/INT0148) examined the effects of increased doses of doxorubicin, above 60 mg per square meter, when combined with cyclophosphamide . . .
Publisher
Massachusetts Medical Society
Subject
/ Antineoplastic Agents, Phytogenic - administration & dosage
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Biological and medical sciences
/ Breast Neoplasms - chemistry
/ Breast Neoplasms - drug therapy
/ Cyclophosphamide - administration & dosage
/ Doxorubicin - administration & dosage
/ Female
/ Fluorescence in situ hybridization
/ Gynecology. Andrology. Obstetrics
/ Humans
/ Paclitaxel - administration & dosage
/ Receptors, Estrogen - analysis
/ Tumors
